Clinical trials: Coagulation Protein Disorders
Hypofibrinogenemia, Congenital, Afibrinogenemia, Congenital
Pregnancy and Fibrinogen Disorders
The aim of this observational study is to evaluate the prevalence of uncomplicated pregnancies in women suffering from congenital fibrinogen disorders (i.e, hypofibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia) as well as…
- Conditions
- Hypofibrinogenemia, Congenital, Afibrinogenemia, Congenital, Dysfibrinogenemia, Congenital
- Trial name
- FIBRINOGEST (NCT03920332)
- Where
- 3 sites in France, Slovakia and 1 more
- Volunteers
- 149 people
- Sponsor
- University Hospital, Geneva
HIV Infections
A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
Study A: To determine whether treatment with zidovudine (ZDV) will delay or change the disease process in hemophilic patients who have HIV infection with no symptoms.
- Trial name
- NCT00001104
- Testing
- Zidovudine
- Where
- 23 sites in United States
- Volunteers
- 538 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Hemophilia A, Hemophilia B
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
The purpose of the study is to determine the efficacy and safety of rFVIIa BI as part of a six-month on-demand treatment regimen in hemophilia A or B subjects with inhibitors.
- Trial name
- NCT01757405
- Testing
- Recombinant Factor VIIa BI (rFVIIa BI)
- Where
- 16 sites in United States, Japan and 7 more
- Volunteers
- 40 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
BAX 826 Dose-Escalation Safety Study
1. To assess tolerability and safety of BAX 826 after a single infusion in previously treated patients (PTPs) with severe hemophilia A 2. To determine the pharmacokinetic (PK) parameters of BAX 826 compared to ADVATE 3.
- Trial name
- NCT02716194
- Testing
- BAX 826, Octocog alfa
- Where
- 28 sites in Bulgaria, Germany and 7 more
- Volunteers
- 40 people
- Sponsor
- Baxalta now part of Shire
Hemophilia
Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease
The improvements observed in the care of patients with hemophilia or Willebrand disease have led to an increase in their life expectancy, which today approaches that of the general population.
- Trial name
- M-HEMORRH'AGE (NCT04282486)
- Testing
- Telephone interview
- Where
- France
- Volunteers
- 142 people
- Sponsor
- Hospices Civils de Lyon
Hemophilia B
Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
To characterize the safety and efficacy of rFIX in children less than 6 years of age with severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery.
- Trial name
- NCT00037557
- Testing
- BeneFIX
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hemophilia A
2-cohort Study of Adult Patients With Severe Hemophilia A in Greece
This study is a prospective, single center, observational, 2-cohort study of adult patients with severe Hemophilia A. There is no randomization procedure and all patients will be treated as per usual clinical practice.
- Trial name
- HAMLET (NCT02319070)
- Testing
- Survey
- Where
- Greece
- Volunteers
- 72 people
- Sponsor
- Bayer
Hemophilia A, Congenital, Hemophilia B, Congenital
Factor Product Utilization and Health Outcomes in Patients With Hemophilia
Recombinant factor VIII Fc (rFVIIIFc) and recombinant factor IX Fc (rFIXFc) are extended half-life coagulation factors approved by Health Canada in 2014 for the treatment of severe hemophilia A and B, respectively.
- Trial name
- NCT02796222
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- University of British Columbia
Hemophilia, Postural; Defect
Posture Analysis for Patients With Haemophilia
Hemophilia A and B are inherited disorders characterized by deficient or missing coagulation factors VIII or IX, respectively, of which the main long-term clinical manifestation is joint damage.
- Conditions
- Hemophilia, Postural; Defect, Muscle Disorder
- Trial name
- NCT05173129
- Testing
- Posture Analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Cukurova University
Hemophilia, Arthropathy
PET Imaging of Hemophilic Arthropathy
Repeated hemarthroses in patients with hemophilia may lead to hemophilic arthropathy with marked inflammation and synovial hypertrophy.
- Conditions
- Hemophilia, Arthropathy, Inflammation
- Trial name
- NCT03485170
- Testing
- 18F-FDG PET/CT
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Moderate and Severe Haemophilia
HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound
Ultrasound represents a promising technique for the assessment of joint health in persons with haemophilia (PWH) by non-imaging specialists.
- Trial name
- NCT03237273
- Testing
- HEAD-US scoring system
- Volunteers
- 200 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Hemophilia A
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients' satisfaction with treatment and their quality of life.
- Trial name
- NCT02971930
- Testing
- BAY94-9027
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Hemophilia
Central Sensitisation in Patients With Haemophilia and Degenerative Arthropathy
Introduction: Hemophilic arthropathy is characterized by functional impairments, disabling physical sequelae, and chronic pain. Central pain sensitization describes increased neural excitability characterized by spontaneous or…
- Trial name
- NCT07110675
- Where
- Spain
- Volunteers
- 146 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Hemophilia A
Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO
This study aims to investigate prospectively throughout a period of 3- 6 months and not to exceed 12 months (according to local therapeutic plans) patients experiences of treatment with Factor VIII in the new device named…
- Trial name
- NCT01959919
- Testing
- Refacto FusENGO
- Where
- 19 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Pfizer
Hemophilia B
Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)
In this postmarketing study, the safety of Nonafact® (human coagulation factor IX) is evaluated in previous treated and untreated patients with severe, moderate or mild haemophilia B.
- Trial name
- NCT00139828
- Testing
- human coagulation Factor IX
- Where
- 7 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Prothya Biosolutions
Hemophilia A
Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A
The aim of this study are to assess the efficacy of Biostate® [Study Product (SP)] in subjects with Haemophilia A compare the pharmacokinetics of Biostate® [SP] with the previously marketed product Biostate® (here referred to as…
- Trial name
- NCT00879541
- Testing
- Biostate® [SP], Biostate® [RP]
- Where
- 14 sites in Bulgaria, North Macedonia and 2 more
- Volunteers
- 81 people
- Sponsor
- CSL Behring
Blood Disease, Hepatitis, Viral, Human
Hepatitis Delta Infections in Hemophiliacs
To elucidate the role of hepatitis delta virus (HDV) in the development of chronic liver disease in patients with hemophilia.
- Conditions
- Blood Disease, Hepatitis, Viral, Human, Liver Diseases, Hemophilia A
- Trial name
- NCT00005305
- Testing
- No interventions - observational study
- Volunteers
- 61 people
- Sponsor
- University of North Carolina, Chapel Hill
Hemophilia B
Hemophilia B Gene Therapy With AAV8 Vector
Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding.
- Trial name
- NCT01620801
- Testing
- AAV8-hFIX19
- Where
- 3 sites in United States, Australia
- Volunteers
- 4 people
- Sponsor
- Spark Therapeutics, Inc.
Hemophilia, Chronic Pain
Multimodal Telerehabilitation Versus Face-to-Face Care for Adults With Hemophilia and Chronic Pain
Hemophilia is an inherited bleeding disorder that is commonly associated with chronic joint pain, reduced physical function, and decreased quality of life.
- Trial name
- HEMO-TELE (NCT07682519)
- Testing
- other, Exercise
- Where
- Chile
- Volunteers
- 24 people
- Sponsor
- University of Chile
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.